Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Drug May Benefit Patients with Heart Failure
Clinical Breakthroughs

Drug May Benefit Patients with Heart Failure

By Melissa RohmanNov 29, 2021
Share
Facebook Twitter Email
Sadiya Khan, ’09 MD, ’14 MSc, ’10, ’12 GME, assistant professor of Medicine in the Division of Cardiology and of Preventive Medicine in the Division of Epidemiology, was a co-author of the study published in Nature Medicine.

Dapagliflozin, a drug commonly used to treat type 2 diabetes, improved symptoms and physical limitations in patients with heart failure with preserved ejection fraction, according to clinical trial results published in Nature Medicine.

Sadiya Khan, ’09 MD, ’14 MSc, ’10, ’12 GME, assistant professor of Medicine in the Division of Cardiology and of Preventive Medicine in the Division of Epidemiology, and Sanjiv Shah, ’00 MD, the Neil J. Stone, MD, Professor and director of the Center for Deep Phenotyping and Precision Therapeutics at the Institute for Augmented Intelligence in Medicine, were co-authors of the study.

Heart failure with preserved ejection fraction (HFpEF) occurs when the heart’s lower left chamber is unable to fill with blood properly. The condition accounts for approximately half of all heart failure cases and disproportionally affects older individuals. Patients with HFpEF can experience a host of debilitating symptoms linked to cardiometabolic abnormalities, including physical limitations, impaired cognition and poor quality of life.

Improving patients’ health and developing or identifying therapeutic interventions that not only reduce hospitalization but also improve patient survival is key, according to the authors, but there are currently no available treatments that improve patient survival for patients with HFpEF.

Previous research demonstrated that sodium glucose cotransporter 2 (SGLT2) inhibitors, drugs that inhibit SGLT2 receptor proteins produced by the kidneys and which are currently used to treat type 2 diabetes, reduced risk of cardiovascular death and heart failure-related hospitalization in patients with HFpEF.

Sanjiv Shah, ’00 MD, the Neil J. Stone, MD, Professor and director of the Center for Deep Phenotyping and Precision Therapeutics at the Institute for Augmented Intelligence in Medicine, was a co-author of the study.

In the current clinical trial, the investigators measured patient-reported symptoms, physical limitations and function in patients with HFpEF who were given the SGLT2 inhibitor drug dapagliflozin.

A total of 324 patients with HFpEF from across the U.S. were randomized to receive either dapagliflozin or placebo for 12 weeks and at the end of the trial were evaluated using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, a measure of heart failure-related health status.

Patients were also 56.8 percent women, who are more likely to develop HFpEF than men.

“It’s important to note the percentage of women that were enrolled in this study because usually women are under-enrolled in clinical trials,” Khan said.

The investigators found that the dapagliflozin group demonstrated overall improvement in patient-reported symptoms, physical limitations and exercise function compared to the placebo group. Adverse events were also similar between both groups, according to the authors.

“It was definitely surprising and very exciting to see such a stark difference between the treatment group and the placebo group, that there was this clear separation that happened even over a short period of time,” Khan said, adding that next steps will be to investigate dapagliflozin’s precise molecular mechanisms that enable its effectiveness.

This work was supported by the American Heart Association grant 19TPA34890060, National Institute of Health grants R01 HL107577, R01 HL127028, R01 HL140731 and R01 HL149423, Actelion, AstraZeneca, Corvia, Novartis and Pfizer.

Cardiology Medicine Preventive Medicine Research
Share. Facebook Twitter Email

Related Posts

Shortage of Mental Health Professionals Linked to Increase in Youth Suicides

Jan 25, 2023

Understanding How Childhood Brain Tumors Develop

Jan 23, 2023

Medical School Establishes New Center for Psychiatric Neuroscience

Jan 19, 2023

Comments are closed.

Latest News

Changes in Medical School Leadership

Jan 26, 2023

Shortage of Mental Health Professionals Linked to Increase in Youth Suicides

Jan 25, 2023

Northwestern Medicine Scholars Program Inspires a New Generation of Physicians and Scientists 

Jan 24, 2023

Understanding How Childhood Brain Tumors Develop

Jan 23, 2023

Medical School Establishes New Center for Psychiatric Neuroscience

Jan 19, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.